Brief: Aridis Reports Top-Line Results Of Late-Stage Trial Of Ventilator Associated Pneumonia

Aridis Pharmaceuticals

25/01/2023 22:16

Jan 25 (Reuters) - Aridis Pharmaceuticals Inc  ARDS.O :
    * ARIDIS REPORTS TOP-LINE RESULTS OF THE PHASE 3
DOUBLE-BLINDED,
SUPERIORITY TRIAL OF AR-301 FOR THE TREATMENT OF STAPHYLOCOCCUS
AUREUS VENTILATOR ASSOCIATED PNEUMONIA (VAP)
    * ARIDIS PHARMACEUTICALS INC - PLANS TO INITIATE A SECOND
PHASE 3
STUDY AFTER DISCUSSING CURRENT STUDY RESULTS WITH REGULATORY
AUTHORITIES
    * ARIDIS PHARMACEUTICALS INC - NONE OF DEATHS IN STUDY WERE
DEEMED
DRUG-RELATED BY BLINDED INVESTIGATORS
    * ARIDIS PHARMACEUTICALS INC - PRIMARY OUTCOME MEASURES OF
SAFETY
AND TOLERABILITY OF AR-301 WERE ACHIEVED
    * ARIDIS PHARMACEUTICALS INC - AR-301 INTRAVENOUS (IV)
INFUSION
WAS WELL TOLERATED

Source text for Eikon:  ID:nGNX9bYHmk 
Further company coverage:  ARDS.O 
 ((Reuters.Briefs@thomsonreuters.com;))